Catalog No.
DHJ62201
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
FGF-inducible 14, TNFRSF12A, FN14, CD266, TweakR, Fibroblast growth factor-inducible immediate-early response protein 14, Tweak-receptor, Tumor necrosis factor receptor superfamily member 12A
Concentration
3.33 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9NP84
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
PDL 192, CAS: 1062149-33-0
Clone ID
Enavatuzumab
Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells, PMID: 29075649
Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors, PMID: 29054986
Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR, PMID: 24409185
Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb, PMID: 23073510
Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts, PMID: 25375638
Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity, PMID: 23532848
Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms, PMID: 20068083
For research use only. Not for human or drug use.
